Results 221 to 230 of about 27,181 (240)
Some of the next articles are maybe not open access.
Meningococcal conjugate vaccines
Expert Opinion on Biological Therapy, 2005Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Polysaccharide meningococcal vaccines have been available for > 20 years, and have been used in travellers to control outbreaks, and in some countries for adolescents entering college, although they provide only a short duration of immunity and do
openaire +2 more sources
Meningococcal Vaccines and Vaccine Developments
2003Despite rapid advances in the diagnosis of bacterial infections and the availability of effective antibiotics, meningococcal disease continues to represent a substantial public health problem for most countries (1-4). Disease usually develops rapidly, is notoriously difficult to distinguish from other febrile illnesses, and generally has a high case ...
openaire +2 more sources
Bioanalysis of Meningococcal Vaccines
Bioanalysis, 2010Meningococcal meningitis is feared because of the rapid onset of severe disease from mild symptoms and, therefore, is an important target for vaccine research. Five serogroups, defined by the structures of their capsular polysaccharides, are responsible for the vast majority of disease.
Neil, Ravenscroft +2 more
openaire +2 more sources
Meningococcal tetravalent conjugate vaccine
Expert Opinion on Biological Therapy, 2008Neisseria meningitidis is a leading cause of meningitis and sepsis worldwide. Since 1981, a tetravalent meningococcal polysaccharide vaccine has been available in the US but it has been limited to high-risk patients and outbreak settings. In 2005, a tetravalent polysaccharide meningococcal conjugate vaccine (MCV4) was licensed for routine use in the US.
openaire +2 more sources